Targeting insulin-like growth factor receptor 1 (IGF-1R) and insulin receptor signaling by tyrosine kinase inhibitors in cancer

Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics

Volumn , Issue , 2012, Pages 215-229

  Carboni, Joan M ^a   Wittman, Mark ^b   Huang, Fei ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b DMCP ^*  (United States)

^c DMCP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877816713     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0598-6_11     Document Type: Chapter

References (108)

1. Andrews DW, et al. (2001). J Clin Oncol 19(8): 2189-200.
2. Arteaga CL and Osborne CK (1989). Cancer Res 49(22): 6237-41.
3. Beech DJ, et al. (2001). Oncol Rep 8(2): 325-9.
4. Belfiore A (2007). Curr Pharm Des 13(7): 671-86.
5. Byron SA, et al. (2006). Br J Cancer 95(9): 1220-8.
6. Camirand A, et al. (2005). Breast Cancer Res 7(4): R570-9.
7. Campbell RA, et al. (2001). J Biol Chem 276(13): 9817-24.
8. Cao L, et al. (2008). Cancer Res 68(19): 8039-48.
9. Carboni JM, et al. (2005). Cancer Res 65(9): 3781-7.
10. Carboni JM, et al. (2009). Mol Cancer Ther 8(12): 3341-9.
11. Carden CP, et al. (2009a). Clin Pharmacol Ther 85(2): 131-3.
12. Carden CP, et al. (2009b). J Clin Oncol (Meeting Abstracts) 27(15S): Abstract 3544.
13. Casa AJ, et al. (2008). Frontiers in Bioscience 13: 3273-87.
14. Chakraborty AK, et al. (2008). Cancer Res 68(5): 1538-45.
15. Chan JM, et al. (1998). Science 279(5350): 563-6.
16. Chu KC, et al. (2001). Cancer 92(1): 37-45.
17. Clemens PL, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract A101.
18. Cortes J, et al. (2008). ASH Annual Meeting Abstracts 112(11): Abstract 3232.
19. Cosaceanu D, et al. (2007). Oncogene 26(17): 2423-34.
20. Cunningham MP, et al. (2006). Int J Oncol 28(2): 329-35.
21. D'Ambrosio C, et al. (1996). Cancer Res 56(17): 4013-20.
22. D'cunja J, et al. (2007). Eur J Cancer 43(10): 1581-9.
23. Desai J, et al. (2010). J Clin Oncol (Meeting Abstracts) 28(7S): Abstract 3104.
24. Desbois-Mouthon C, et al. (2009). Clin Cancer Res 15(17): 5445-56.
25. Dinchuk JE, et al. (2010). Endocrinology: manuscript submitted.
26. Dunn SE, et al. (1997). Cancer Res 57(13): 2687-93.
27. Engelman JA, et al. (2005). Proc Natl Acad Sci USA. 102(10): 3788-93.
28. Frasca F, et al. (1999). Mol Cell Biol 19(5): 3278-88.
29. Garcia-Echeverria C, et al. (2004). Cancer Cell 5(3): 231-9.
30. Girnita A, et al. (2004). Cancer Res 64(1): 236-42.
31. Gong Y, et al. (2009). J Clin Oncol (Meeting Abstracts) 27(15S): Abstract 8095.
32. Gooch JL, et al. (1999). Breast Cancer Res Treat 56(1): 1-10.
33. Gualberto A and Pollak M (2009). Oncogene 28(34): 3009-21.
34. Haluska P, et al. (2006). Cancer Res 66(1): 362-71.
35. Haluska P, et al. (2007). Proceedings from the 15th SPORE Investigators' Workshop.
36. Haluska P, et al. (2008). Mol Cancer Ther 7(9): 2589-98.
37. Haluska P, et al. (2009). 32nd San Antonio Breast Cancer Symposium.
38. Harmenberg J, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract B256.
39. Harris LN, et al. (2007). Clin Cancer Res. 13(4): 1198-207.
40. Harzstark AL, et al. (2007). J Clin Oncol 25(18S).
41. Hendrickson AW and Haluska P (2009). Curr Opin Investig Drugs 10(10): 1032-40.
42. Hewish M, et al. (2009). Recent Pat Anticancer Drug Discov 4(1): 54-72.
43. Hillerman SM, et al. (2010). Proceedings of the 101st Annual Meeting of the AACR; Abstract 363.
44. Huang F, et al. (2009). Cancer Res 69(1): 161-70.
45. Huang F, et al. (2010). Cancer Res 70(18): 7221-31.
46. Hubbard RD and Wilsbacher JL (2007). ChemMedChem 2(1): 41-6.
47. Ji QS, et al. (2007). Mol Cancer Ther 6(8): 2158-67.
48. Jones HE, et al. (2004). Endocr Relat Cancer 11(4): 793-814.
49. Jones HE, et al. (2006). Br J Cancer 95(2): 172-80.
50. Kalli KR, et al. (2002). Endocrinology 143(9): 3259-67.
51. Karp DD, et al. (2009). J Clin Oncol 27(15): 2516-22.
52. Kim HJ, et al. (2007). Mol Cell Biol 27(8): 3165-75.
53. Knowlden JM, et al. (2005). Endocrinology 146(11): 4609-18.
54. Kobayashi S, et al. (2005). N Engl J Med. 352(8): 786-92.
55. Kostler WJ, et al. (2006). J Cancer Res Clin Oncol 132(1): 9-18.
56. Lee AV, et al. (1997). J Endocrinol 152(1): 39-47.
57. Lee J, et al. (2007). Mol Pharmacol. 72(4): 1082-93.
58. LeRoith D, et al. (1995). Ann Intern Med 122(1): 54-9.
59. Li R, et al. (2009). J Med Chem 52(16): 4981-5004.
60. Lindsay CR, et al. (2009). J Clin Oncol (Meeting Abstracts) 27(15S): Abstract 2559.
61. Litzenburger BC, et al. (2009). 32nd San Antonio Breast Cancer Symposium.
62. Long L, et al. (1995). Cancer Res 55(5): 1006-9.
63. Lu Y, et al. (2001). J Natl Cancer Inst 93(24): 1852-7.
64. Macaulay VM, et al. (2001). Oncogene 20(30): 4029-40.
65. Maiso P, et al. (2008). Br J Haematol 141(4): 470-82.
66. Martins AS, et al. (2008). Cancer Res 68(15): 6260-70.
67. Min Y, et al. (2005). Gut 54(5): 591-600.
68. Mitsiades CS, et al. (2004). Cancer Cell 5(3): 221-30.
69. Moller DE, et al. (1989). Mol Endocrinol 3(8): 1263-9.
70. Morgillo F, et al. (2006). Cancer Res 66(20): 10100-11.
71. Morgillo F, et al. (2007). Clin Cancer Res 13(9): 2795-803.
72. Mukohara T, et al. (2009). Cancer Lett 282(1): 14-24.
73. Mulvihill M, et al. (2008). Proceedings of the 101st Annual Meeting of the AACR; Abstract 4893.
74. Nahta R, et al. (2005). Cancer Res 65(23): 11118-28.
75. Nahta R, et al. (2007). Mol Cancer Ther 6(2): 667-4.
76. Nakamura S, et al. (1997). Exp Cell Res. 235(1): 287-94.
77. Pandini G, et al. (1999). Clin Cancer Res 5(7): 1935-44.
78. Pandini G, et al. (2002). J Biol Chem 277(42): 39684-95.
79. Pao W, et al. (2005). PLoS Med. 2(3): e73.
80. Perer ES, et al. (2000). J Surg Res 94(1): 1-5.
81. Peretz S, et al. (2001). Proc Natl Acad Sci U S A. 98(4): 1676-81.
82. Peruzzi F, et al. (1999). Mol Cell Biol 19(10): 7203-15.
83. Pietrzkowski Z, et al. (1993). Cancer Res 53(5): 1102-6.
84. Pitts TM, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract A39.
85. Pollak M (2008). Curr Opin Pharmacol 8(4): 384-92.
86. Sciacca L, et al. (1999). Oncogene 18(15): 2471-9.
87. Sciacca L, et al. (2002). Oncogene 21(54): 8240-50.
88. Scotlandi K, et al. (2005). Cancer Res 65(9): 3868-76.
89. Smith DC, et al. (2010). J Clin Oncol (Meeting Abstracts) 28(7S): Abstract 3105.
90. Tan AC, et al. (2009). Molecular Cancer Therapeutics 8(12): Abstract C22.
91. Turner BC, et al. (1997). Cancer Res 57(15): 3079-83.
92. Ulanet DB, et al. (2010). Proc Natl Acad Sci USA.
93. Valentinis B and Baserga R (2001). Mol Pathol 54(3): 133-7.
94. van der Veeken J, et al. (2009). Curr Cancer Drug Targets 9(6): 748-60.
95. Velaparthi U, et al. (2008). J Med Chem 51(19): 5897-900.
96. Vella V, et al. (2002). J Clin Endocrinol Metab 87(1): 245-54.
97. Warshamana-Greene GS, et al. (2004). Mol Cancer Ther 3(5): 527-35.
98. Warshamana-Greene GS, et al. (2005). Clin Cancer Res 11(4): 1563-71.
99. Wen B, et al. (2001). Br J Cancer 85(12): 2017-21.
100. Weroha SJ and Haluska P (2008). J Mammary Gland Biol Neoplasia 13(4): 471-83.
101. Wittman MD, et al. (2009a). J Med Chem 52(23): 7360-3.
102. Wittman MD, et al. (2009b). Annual Reports in Medicinal Chemistry 44: 281-299.
103. Zha J, et al. (2009). Mol Cancer Ther 8(8): 2110-21.
104. Zhang H, et al. (2007). J Clin Invest. 117(8): 2051-8.
105. Zhang H, et al. (2010). Oncogene in press.
106. Zhou DJ, et al. (1990). Cancer Res 50(21): 6949-54.
107. Zimmermann K, et al. (2008). Bioorg Med Chem Lett 18(14): 4075-80.
108. Zimmermann K, et al. (2010). Bioorg Med Chem Lett 20(5): 1744-8.